Will InMed Pharmaceuticals stock go up?

According to Danelfin AI, InMed Pharmaceuticals has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (42.31%) is -8.50% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for InMed Pharmaceuticals stock?

The InMed Pharmaceuticals target price is $490.09 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold InMed Pharmaceuticals stock right now?

InMed Pharmaceuticals has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (42.31%) is -8.50% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether InMed Pharmaceuticals stock is a good buy .

Is InMed Pharmaceuticals undervalued right now?

Based on analysts, the average price target upside for InMed Pharmaceuticals is +30,340.26% (1Y). According to Danelfin AI, InMed Pharmaceuticals has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of InMed Pharmaceuticals stock over the past 12 months?

The InMed Pharmaceuticals stock price range over the past 12 months has been $0.62 - $3.87.

What is going on with InMed Pharmaceuticals stock in the last 3 months?

The InMed Pharmaceuticals stock performance in the last quarter has been +149.65%.

Does InMed Pharmaceuticals offer dividend payments?

No, InMed Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of InMed Pharmaceuticals?

InMed Pharmaceuticals's market cap is $5.27M, as of 2026-07-02 08:00.

InMed Pharmaceuticals Inc (INM) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

INM AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Volatility+0.02%
How much the stock price tends to fluctuate

Valuation-2.45%
How the stock is priced relative to its fundamentals
Momentum-2.34%
Direction and strength of recent price movements
Size & Liquidity-1.35%
Company size and trading liquidity
Profitability-0.86%
Profitability and operating efficiency metrics
Earnings Quality-0.71%
Stability and reliability of reported earnings
Sentiment-0.54%
How analysts and the market view the stock
Growth-0.28%
Expected pace of revenue and earnings expansion

INM probability advantage of beating the market (3M):

-8.50%

AI Score

Strong Sell

InMed Pharmaceuticals (INM) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -8.50% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of INM (42.31%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
INM probability advantage of beating the market (3M)-8.50%
INM probability of beating the market (3M)42.31%

INM probability advantage of beating the market (3M): -8.50%

The AI-powered overall analysis of InMed Pharmaceuticals (INM) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of INM:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-1.49%
Technical	Technicals Impact (Long Tail)	-	N/A	+1.43%
Technical	Chart Pattern (252d)	figure_60	N/A	-1.32%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.18%
Technical	Chart Pattern (120d)	figure_148	N/A	-1.03%
Fundamental	Beginning Cash (Millions)	10.74		-0.99%
Technical	ATR (14d Volatility)	0.1	N/A	+0.98%
Technical	Chart Pattern (60d)	figure_19	N/A	-0.95%
Sentiment	Industry (GICS)	Pharmaceuticals	N/A	+0.82%
Technical	Plus Directional Indicator (+DI, 90d)	28.21%		-0.76%
Fundamental	Upgrade to unlock			-0.71%
Fundamental	Upgrade to unlock			-0.56%
Technical	Upgrade to unlock			-0.54%
Fundamental	Upgrade to unlock			-0.54%
Sentiment	Upgrade to unlock			-0.51%

Rest of Alpha Signals: -1.15%

INM probability advantage of beating the market (3M)Total:-8.50%
INM AI Score

Significant changes Vs previous day

INM Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.61
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

INM Proven Sell Signal & Price Forecast

This is the price chart for INM from January 1, 2026 until today. The chart indicates, in red, the 38 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

INM Average Past Performance & Loss Rate

Three months after its 871 Sell signals since July 2026, INM had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

871 Past INM Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-79.77%
Average Alpha				-88.32%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

INM Frequently Asked Questions

Will InMed Pharmaceuticals stock go up?
According to Danelfin AI, InMed Pharmaceuticals has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (42.31%) is -8.50% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for InMed Pharmaceuticals stock?
Is it a good time to buy, sell, or hold InMed Pharmaceuticals stock right now?
Is InMed Pharmaceuticals undervalued right now?
What was the price range of InMed Pharmaceuticals stock over the past 12 months?
What is going on with InMed Pharmaceuticals stock in the last 3 months?
Does InMed Pharmaceuticals offer dividend payments?
What is the current market capitalization of InMed Pharmaceuticals?

InMed Pharmaceuticals Inc Company Profile

InMed Pharmaceuticals Inc., a clinical-phase pharmaceutical establishment, dedicates its efforts to innovatively developing a spectrum of prescription-oriented commodities. The operations of the company are bifurcated into two sectors - InMed and BayMedica.

The InMed sector actively partakes in rigorous research for the advancement of cannabinoid-centric pharmaceutical creations while the BayMedica subdivision focuses on originating exceptional manufacturing methodologies aimed at producing and vending rare cannabinoids purposed for the health and rejuvenation industry.

Its chain of prescription-oriented innovations comprises rare cannabinoids along with revolutionary cannabinoid analogs that propose treatments for diseases embodied by substantial yet unfulfilled medical necessities. The flagship product from this collection, INM-755, manifests as a topical skin cream infused with cannabinol which has successfully completed Phase 2 clinical trials pertaining to the treatment of epidermolysis bullosa. The research portfolio also features INM-088, presently in its preclinical phase targeting glaucoma treatment, and INM-900 conceived for combatting neurodegenerative diseases.

Furthermore, InMed Pharmaceuticals introduces IntegraSyn, an intricate approach integrating biosynthesis-aligned manufacturing protocol suitable for pharmaceutical-level cannabinoids; alongside extending offerings such as cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.

Previously branded as Cannabis Technologies Inc., it underwent renaming to InMed Pharmaceuticals Inc. in October 2014. Originating back to 1981 when it was formally instituted, InMed Pharmaceuticals Inc. operates from their primary offices centered in Vancouver, Canada.

Sector:Health Care
Country:Canada
Industry:Pharmaceuticals
Address:#709 - 1445 West Georgia Street, Vancouver
Employees:0
Website:inmedpharma.com

Pros

Proprietary enzymatic cannabinoid synthesis platform

Diversified pipeline targeting multiple therapeutic areas

Potential for novel cannabinoid intellectual property

Addressing unmet medical needs with cannabinoid mechanisms

Expanding scientific and regulatory acceptance of cannabinoids

Cons

High capital requirements for drug development

Extended and uncertain clinical trial timelines

Complex and evolving cannabinoid regulatory environment

Competition from larger pharmaceutical enterprises

Dependence on successful clinical trial results

Company	AI Score	Compare
INSMInsmed Inc
IMCCIM Cannabis Corp
INMBINmune Bio Inc
MNOVMediciNova Inc
IMAImageneBio Inc

Company	AI Score	Compare
INSMInsmed Inc
IMCCIM Cannabis Corp
INMBINmune Bio Inc
MNOVMediciNova Inc
IMAImageneBio Inc

INM Stock AI Analysis